Oncology Articles

Apolo Discusses Immunotherapy Advances in Bladder Cancer
Andrea Apolo, MD, discusses positive early trials exploring various regimens of nivolumab (Opdivo), ipilimumab (Yervoy), and avelumab in bladder cancer.
Researchers Examine Acquired Mutations Linked to Ibrutinib Resistance in CLL
Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.
Vaccine Limits Herpes Zoster Infections Following Stem Cell Transplant
Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.
Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT
Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.
EC Approves Alectinib for ALK+ NSCLC
The European Commission has approved alectinib (Alecensa) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer following progression on crizotinib (Xalkori).
Carfilzomib Maintenance Improves Response Following Transplant in Relapsed Multiple Myeloma
According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.
Daratumumab Triplets Recommended for EU Approval in Myeloma
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.
CHMP Recommends Dabrafenib/Trametinib Combo in BRAF+ NSCLC
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) as a treatment for patients with advanced or metastatic BRAF V600E-mutant non-small cell lung cancer.
Endometrial Cancer Survivors at High Risk for Cardiotoxicity
A new study has provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.
Pembrolizumab Long-Term Survival Rate Could Reach 25% in NSCLC
Treatment with pembrolizumab could elicit long-term survival rates of 21% to 25% for previously-treated patients with PD-L1–positive non–small cell lung cancer compared with 3% to 4% for docetaxel.
Publication Bottom Border
Border Publication